Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 594 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diffuse Parenchymal Lung Disease Clear all
Completed Phase 2 Interventional Results available

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

NCT04308681
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
BMS-986278 Placebo, BMS-986278
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Recruiting No phase listed Observational

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

NCT04098445
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 24 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
9
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 4 Interventional

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 8, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis

NCT02958917
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Pirfenidone, Placebo controlled
Drug · Other
Lead sponsor
Evans Fernandez Perez
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease

NCT03215927
View directory record Official record
Conditions
Myositis, Interstitial Lung Disease
Interventions
Abatacept, Placebo
Drug · Other
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Not applicable Interventional Results available

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

NCT01982968
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Interventions
Surgery
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)

NCT03929120
View directory record Official record
Conditions
Interstitial Lung Disease, Connective Tissue Diseases
Interventions
Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT02477709
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Gefapixant
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 8, 2026, 5:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography

NCT00001759
View directory record Official record
Conditions
Asthma, Hypersensitivity, Lung Diseases, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

NCT03928847
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Epigallocatechin-3-gallate (EGCG)
Drug
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 8, 2026, 5:17 AM EDT
Recruiting Phase 2 Interventional

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

NCT05417776
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
[68Ga]CBP8, Dotarem
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

NCT02370693
View directory record Official record
Conditions
Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
Interventions
Bortezomib, Placebo, Mycophenolate mofetil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 8, 2026, 5:17 AM EDT
Completed No phase listed Observational

Pulmonary Fibrosis Foundation Patient Registry

NCT02758808
View directory record Official record
Conditions
Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Not listed
Lead sponsor
Pulmonary Fibrosis Foundation
Other
Eligibility
18 Years to 99 Years
Enrollment
2,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Results available

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

NCT01619085
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
37
States / cities
Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Lebrikizumab, Pirfenidone, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 2 Interventional

Steroids and Methotrexate to Treat Systemic Vasculitis

NCT00001256
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
prednisone and methotrexate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

NCT06360094
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
BI 1839100, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

NCT01531257
View directory record Official record
Conditions
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Terminated Not applicable Interventional

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006054
View directory record Official record
Conditions
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
Up to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 8, 2026, 5:17 AM EDT
Recruiting No phase listed Observational

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT03004326
View directory record Official record
Conditions
Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
Interventions
Not listed
Lead sponsor
Peter Merkel
Other
Eligibility
5 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
96
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 8, 2026, 5:17 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Lenalidomide for Adult Histiocyte Disorders

NCT02523040
View directory record Official record
Conditions
Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
Interventions
Lenalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Terminated Phase 2 Interventional Results available

LYT-100 in Post-acute COVID-19 Respiratory Disease

NCT04652518
View directory record Official record
Conditions
Covid19, Post-acute COVID-19 Respiratory Disease
Interventions
LYT-100, Placebo
Drug · Other
Lead sponsor
PureTech
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Florence, Alabama • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 8, 2026, 5:17 AM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 8, 2026, 5:17 AM EDT